IBTFvsXBI
iShares iBonds Dec 2025 Term Treasury ETF against SPDR S&P Biotech ETF — the fee, the flows, the book, and a year head-to-head.
Head to head
| IBTF | XBI | |
|---|---|---|
| Expense ratio | 0.070% | 0.35% |
| Assets | $1.4B | $10.3B |
| Net flow, 1 month | — | −$455M |
| Net flow, 1 year | −$367M | +$891M |
| Return, YTD | — | +23.2% |
| Return, 1 year | -0.0% | +44.9% |
| Avg daily volume | — | 9.3M |
| Holdings | 32 | 135 |
| Listed | Feb 25, 2020 | Jan 31, 2006 |
| Options market | No | Yes |
MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS